EXPLORE!

CMAAO Coronavirus Facts and Myth Buster - PreventCOVIDU trial

  1628 Views

Dr KK Aggarwal    01 April 2021

With input from Dr Monica Vasudev

  1. Thousands of college students are participating in a new trial – PreventCOVIDU. The trial is aimed at evaluating how well COVID-19 vaccines decrease the risk of COVID-19 transmission.
  2. The open-label randomized trial aims to assess if vaccine prevents both infection and transmission of SARS-CoV-2 among college students.
  3. This NIH-funded study will include 12,000 college students, 18 to 26 years of age, from over 20 universities, and may last for 5 months.
  4. A total of 6,000 students will be administered their first dose of the Moderna vaccine immediately while others will serve as controls and will be given their vaccine after 4 months.
  5. All participants will eventually be given the usual two doses.
  6. Participants will swab their noses every day, provide blood samples periodically, and complete surveys via an electronic diary app. They will also follow their universitys COVID-19 protocols and will be tested twice a week.
  7. Another 25,000 individuals whom participants will identify as close contacts will also be required to provide blood samples, take daily nose swabs for 2 weeks, and answer weekly questionnaires.
  8. Investigators will ascertain the degree of transmission from vaccinated individuals by the infection rate in close contacts.
  9. Participants will be paid for the daily swab collection, with the amount depending on locations and other factors.
  10. Exclusion criteria for the trial include: Self-reported history of SARS-CoV-2 infection; having received blood products, systemic immunoglobulins, or monoclonal antibodies (including against SARS-CoV-2) within 90 days prior to first vaccination; and having received of investigational research agents within 30 days prior to first vaccination.
  11. Additionally, students who have already received a COVID-19 vaccine dose, have been given an immunosuppressive medication within 168 days, or have a clinically significant medical condition are not eligible to participate in the study. (Medpage Today)

 

Dr KK Aggarwal

President CMAAO, HCFI and Past National President IMA

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.